Zoryve is a Arcutis Biotherapeutics product.
Arcutis Biotherapeutics
Founded in 2016, Arcutis is a clinical-stage biopharmaceutical company innovating in medical dermatology.
Founded
2016Founded in 2016, Arcutis is a clinical-stage biopharmaceutical company innovating in medical dermatology.
Founded in 2016, Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to addressing significant unmet needs in medical dermatology. The company's core mission is to develop and commercialize best-in-class products that make meaningful advances in the treatment of immune-mediated skin diseases. Arcutis leverages its extensive expertise in medical dermatology to create innovative solutions that solve everyday challenges for patients and healthcare professionals.
Arcutis has attracted notable investors and affiliations, including its listing on Nasdaq under the ticker ARQT. The company has achieved significant milestones in its clinical trials, demonstrating promising results for its pipeline products. By focusing on meaningful innovation and patient-centric solutions, Arcutis has made a substantial impact in the field of dermatology, aiming to improve the quality of life for individuals affected by chronic skin conditions.
Companies similar to Arcutis Biotherapeutics include Dermavant Sciences, DermBiont, Aclaris Therapeutics and Fortress Biotech.
Arcutis Biotherapeutics was founded in 2016.
Arcutis Biotherapeutics' headquarters is located in Westlake Village, CA, US.
Arcutis Biotherapeutics' most recent funding round was for $100M (USD) in October 2023.
As of Oct 19, 2023, Arcutis Biotherapeutics has disclosed funding of $683.5M (USD). Undisclosed round amounts are excluded.
Arcutis Biotherapeutics has 268 employees as of Feb 6, 2024.
Fortress Biotech